Anthera Pharmaceuticals, Inc.
ANTH
ANTH was delisted on the 27th of June, 2018.
32 hedge funds and large institutions have $35.7M invested in Anthera Pharmaceuticals, Inc. in 2013 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 9 closing their positions.
8% more capital invested
Capital invested by funds: $32.9M → $35.7M (+$2.73M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
9% less funds holding
Funds holding: 35 → 32 (-3)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$1.36M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$1.01M |
| 3 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
+$814K |
| 4 |
BC
Broadfin Capital
New York
|
+$727K |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$268K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
Moore Capital Management
New York
|
-$926K |
| 2 |
VM
VHCP Management
New York
|
-$666K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$592K |
| 4 |
JGC
J. Goldman & Co
New York
|
-$463K |
| 5 |
B
Bailard
Foster City,
California
|
-$255K |
ANTH Hedge Fund Activity: Q3 2013 in Review
32 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Anthera Pharmaceuticals, Inc. (ANTH) for Q3 2013, worth a combined $35.7M — up 8.3% from $32.9M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ANTH and 6 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 10 added.
The largest buyer was Camber Capital Management, adding an estimated $1.36M. The largest seller was Moore Capital Management, exiting entirely with an estimated $926K sold.
- 32 institutional investors held Anthera Pharmaceuticals, Inc. (ANTH) as of Q3 2013, down from 35 in Q2 2013.
- Funds reported $35.7M of Anthera Pharmaceuticals, Inc. stock for Q3 2013, up 8.3% quarter-over-quarter.
- 6 funds opened new Anthera Pharmaceuticals, Inc. positions in Q3 2013 and 9 closed out, a net change of -3 holders.
- The largest Anthera Pharmaceuticals, Inc. buyer in Q3 2013 was Camber Capital Management, an estimated $1.36M added.
- The largest Anthera Pharmaceuticals, Inc. seller in Q3 2013 was Moore Capital Management, an estimated $926K sold.
Based on aggregated 13F filings for Q3 2013.